
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2497241/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010, 42, 937-948.	9.4	2,634
2	Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature, 2010, 467, 832-838.	13.7	1,789
3	A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature, 2008, 452, 638-642.	13.7	1,399
4	Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nature Genetics, 2009, 41, 18-24.	9.4	1,247
5	Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nature Genetics, 2007, 39, 631-637.	9.4	818
6	Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer. Nature Genetics, 2007, 39, 865-869.	9.4	774
7	The present and future burden of urinary bladder cancer in the world. World Journal of Urology, 2009, 27, 289-293.	1.2	772
8	Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nature Genetics, 2007, 39, 977-983.	9.4	670
9	Genetic determinants of hair, eye and skin pigmentation in Europeans. Nature Genetics, 2007, 39, 1443-1452.	9.4	659
10	Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior. Nature Genetics, 2010, 42, 448-453.	9.4	649
11	Many sequence variants affecting diversity of adult human height. Nature Genetics, 2008, 40, 609-615.	9.4	615
12	Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nature Genetics, 2009, 41, 221-227.	9.4	572
13	Rare and low-frequency coding variants alter human adult height. Nature, 2017, 542, 186-190.	13.7	544
14	The global burden of urinary bladder cancer: an update. World Journal of Urology, 2020, 38, 1895-1904.	1.2	504
15	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nature Genetics, 2010, 42, 978-984.	9.4	493
16	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
17	Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer. Nature Genetics, 2008, 40, 703-706.	9.4	412
18	Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nature Genetics, 2008, 40, 1307-1312.	9.4	377

#	Article	IF	CITATIONS
19	Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases. JAMA Oncology, 2017, 3, 636.	3.4	376
20	Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nature Genetics, 2008, 40, 281-283.	9.4	357
21	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
22	Mutations in BRIP1 confer high risk of ovarian cancer. Nature Genetics, 2011, 43, 1104-1107.	9.4	338
23	Two newly identified genetic determinants of pigmentation in Europeans. Nature Genetics, 2008, 40, 835-837.	9.4	331
24	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
25	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nature Genetics, 2009, 41, 991-995.	9.4	321
26	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	9.4	321
27	Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nature Genetics, 2009, 41, 1122-1126.	9.4	313
28	New common variants affecting susceptibility to basal cell carcinoma. Nature Genetics, 2009, 41, 909-914.	9.4	303
29	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	9.4	286
30	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nature Genetics, 2011, 43, 1098-1103.	9.4	251
31	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	9.4	235
32	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
33	Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nature Genetics, 2011, 43, 60-65.	9.4	220
34	Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche. Nature Genetics, 2009, 41, 734-738.	9.4	199
35	Gender differences in stage-adjusted bladder cancer survival. Urology, 2000, 55, 876-880.	0.5	197
36	Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nature Genetics, 2010, 42, 692-697.	9.4	181

#	Article	IF	CITATIONS
37	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nature Genetics, 2012, 44, 1326-1329.	9.4	178
38	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
39	A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nature Genetics, 2010, 42, 415-419.	9.4	169
40	Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. Science Translational Medicine, 2010, 2, 62ra92.	5.8	140
41	European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Human Molecular Genetics, 2011, 20, 4268-4281.	1.4	134
42	Male-pattern baldness susceptibility locus at 20p11. Nature Genetics, 2008, 40, 1282-1284.	9.4	118
43	Sequence variants at CYP1A1–CYP1A2 and AHR associate with coffee consumption. Human Molecular Genetics, 2011, 20, 2071-2077.	1.4	114
44	A variant in FTO shows association with melanoma risk not due to BMI. Nature Genetics, 2013, 45, 428-432.	9.4	111
45	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	0.9	111
46	Familial aggregation of urothelial cell carcinoma. International Journal of Cancer, 2002, 98, 274-278.	2.3	106
47	Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. British Journal of Cancer, 2015, 112, 594-600.	2.9	87
48	No Increased Risk of Cancer after Coal Tar Treatment in Patients with Psoriasis or Eczema. Journal of Investigative Dermatology, 2010, 130, 953-961.	0.3	86
49	Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus. PLoS Genetics, 2010, 6, e1001029.	1.5	82
50	Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 2015, 47, 888-897.	9.4	78
51	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	1.4	68
52	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	5.8	63
53	More Differences Between HNPCC-related and Sporadic Carcinomas From the Endometrium as Compared to the Colon. American Journal of Surgical Pathology, 2004, 28, 706-711.	2.1	62
54	Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). International Journal of Cancer, 2011, 128, 2695-2708.	2.3	58

#	Article	IF	CITATIONS
55	Incidence and prognosis of parathyroid gland carcinoma: A population-based study in The Netherlands estimating the preoperative diagnosis. American Journal of Surgery, 2011, 202, 590-597.	0.9	56
56	A common variant at 8q24.21 is associated with renal cell cancer. Nature Communications, 2013, 4, 2776.	5.8	56
57	Expert review remains important in the histopathological diagnosis of cutaneous melanocytic lesions. Histopathology, 2008, 52, 139-146.	1.6	55
58	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 880-890.	1.1	54
59	Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium. EBioMedicine, 2015, 2, 1677-1685.	2.7	49
60	Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. PLoS ONE, 2011, 6, e24987.	1.1	48
61	Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . Cancer Research, 2014, 74, 852-861.	0.4	48
62	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. Human Molecular Genetics, 2014, 23, 5545-5557.	1.4	46
63	Prevalence of multiple malignancies in the Netherlands in 2007. International Journal of Cancer, 2011, 128, 1659-1667.	2.3	45
64	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	1.1	44
65	Perioperative treatment and radical cystectomy for bladder cancer – a population based trend analysis of 10,338 patients in the Netherlands. European Journal of Cancer, 2016, 54, 18-26.	1.3	44
66	Trends in incidence and mortality of thyroid carcinoma in The Netherlands between 1989 and 2003: Correlation with thyroid fineâ€needle aspiration cytology and thyroid surgery. International Journal of Cancer, 2008, 123, 1681-1684.	2.3	43
67	Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. American Journal of Clinical Nutrition, 2012, 96, 902-910.	2.2	43
68	Melanoma of unknown primary origin: A population-based study in the Netherlands. European Journal of Cancer, 2013, 49, 676-683.	1.3	43
69	Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15–39 Years): A Population-Based Study in The Netherlands 1990–2016. Cancers, 2020, 12, 3421.	1.7	43
70	Epidemiology of Bladder Cancer. European Urology, 1999, 36, 660-672.	0.9	42
71	Pattern of follow-up care and early relapse detection in breast cancer patients. Breast Cancer Research and Treatment, 2012, 136, 859-868.	1.1	40
72	Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes — A Meta-Analysis. EBioMedicine, 2016, 11, 219-226.	2.7	40

#	Article	IF	CITATIONS
73	Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 247-251.	0.8	39
74	Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer—Results of a nationwide population-based study. European Journal of Cancer, 2016, 69, 1-8.	1.3	39
75	The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 166.e1-166.e6.	0.8	39
76	Coal tar in dermatology. Journal of Dermatological Treatment, 2007, 18, 329-334.	1.1	38
77	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Human Molecular Genetics, 2016, 25, 1203-1214.	1.4	38
78	The Epidemiology and Clinicopathological Features of Basal Cell Carcinoma in Patients 80 Years and Older. JAMA Dermatology, 2017, 153, 71.	2.0	38
79	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	0.5	37
80	The effect of the ATG16L1 Thr300Ala polymorphism on susceptibility and outcome of patients with epithelial cell-derived thyroid carcinoma. Endocrine-Related Cancer, 2012, 19, L15-L18.	1.6	34
81	Personal hair dye use and the risk of bladder cancer: a case–control study from The Netherlands. Cancer Causes and Control, 2012, 23, 1139-1148.	0.8	33
82	Segregation analysis of urothelial cell carcinoma. European Journal of Cancer, 2006, 42, 1428-1433.	1.3	30
83	Risk factors for second primary melanoma among Dutch patients with melanoma. British Journal of Dermatology, 2017, 176, 971-978.	1.4	30
84	Smoking intensity and bladder cancer aggressiveness at diagnosis. PLoS ONE, 2018, 13, e0194039.	1.1	29
85	Germline deletions in the tumour suppressor gene <i><scp>FOCAD</scp></i> are associated with polyposis and colorectal cancer development. Journal of Pathology, 2015, 236, 155-164.	2.1	28
86	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	1.1	28
87	Genome-Wide Significant Association Between a Sequence Variant at 15q15.2 and Lung Cancer Risk. Cancer Research, 2011, 71, 1356-1361.	0.4	26
88	Fruit and vegetable consumption and risk of aggressive and non-aggressive urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition. European Journal of Cancer, 2012, 48, 3267-3277.	1.3	26
89	Site-specific familial aggregation of prostate cancer. International Journal of Cancer, 2004, 109, 611-617.	2.3	25
90	Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncology, 2020, 16, 1371-1384.	1.1	25

#	Article	IF	CITATIONS
91	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
92	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	1.3	24
93	Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response. Bladder Cancer, 2016, 2, 77-89.	0.2	24
94	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	1.8	23
95	Radical prostatectomy versus deferred treatment for localised prostate cancer. The Cochrane Library, 2020, 6, CD006590.	1.5	23
96	Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch populationâ€based study from 1993 to 2017. BJU International, 2021, 128, 343-351.	1.3	23
97	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
98	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	0.6	22
99	Insertion of an SVA-E retrotransposon into the <i>CASP8</i> gene is associated with protection against prostate cancer. Human Molecular Genetics, 2016, 25, 1008-1018.	1.4	22
100	Intravesical Radiofrequency-Induced Chemohyperthermia for Carcinoma in Situ of the Urinary Bladder: A Retrospective Multicentre Study. Bladder Cancer, 2018, 4, 365-376.	0.2	22
101	Prognostic Relevance of Urinary Bladder Cancer Susceptibility Loci. PLoS ONE, 2014, 9, e89164.	1.1	20
102	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	1.8	19
103	Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer. BJU International, 2018, 122, 535-548.	1.3	19
104	Nationwide treatment patterns and survival of older patients with prostate cancer. Journal of Geriatric Oncology, 2019, 10, 252-258.	0.5	19
105	Guideline adherence for the surgical treatment of T1 renal tumours correlates with hospital volume: an analysis from the British Association of Urological Surgeons Nephrectomy Audit. BJU International, 2020, 125, 73-81.	1.3	19
106	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
107	Successful centralisation of patients with vulvar carcinoma: A population-based study in The Netherlands. European Journal of Cancer, 2012, 48, 1997-2003.	1.3	16
108	Consortium analysis of gene and gene–folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	1.5	16

#	Article	IF	CITATIONS
109	Dermatological exposure to coal tar and bladder cancer risk: A case-control study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 20.e19-20.e22.	0.8	16
110	The prognostic value of family history among patients with urinary bladder cancer. International Journal of Cancer, 2015, 136, 1117-1124.	2.3	16
111	Analysis of 105.000 patients with cancer: have they been discussed in oncologic multidisciplinary team meetings? A nationwide population-based study in the Netherlands. European Journal of Cancer, 2019, 121, 85-93.	1.3	16
112	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	0.6	15
113	Prognostic Factors for Survival in Patients With Recurrence of Muscle Invasive Bladder Cancer After Treatment With Curative Intent. Clinical Genitourinary Cancer, 2011, 9, 14-21.	0.9	14
114	DNA adducts in skin biopsies and 1-hydroxypyrene in urine of psoriasis patients and healthy volunteers following treatment with coal tar. Toxicology Letters, 2012, 213, 39-44.	0.4	14
115	Bladder cancer survival: Women only fare worse in the first two years after diagnosis. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 853-861.	0.8	14
116	Adherence to guideline recommendations for management of clinical T1 renal cancers in the Netherlands: a population-based study. World Journal of Urology, 2016, 34, 1053-1060.	1.2	13
117	The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life. BMJ Open, 2019, 9, e030396.	0.8	13
118	Known susceptibility SNPs for sporadic prostate cancer show a similar association with "hereditary― prostate cancer. Prostate, 2015, 75, 474-483.	1.2	12
119	Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice. Acta Oncológica, 2016, 55, 423-429.	0.8	12
120	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	1.1	12
121	No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression. PLoS ONE, 2020, 15, e0229384.	1.1	12
122	Spouse controls in family case-control studies: a methodological consideration. Familial Cancer, 2003, 2, 101-108.	0.9	11
123	Treatment policy for psoriasis and eczema: a survey among dermatologists in the Netherlands and Belgian Flanders. European Journal of Dermatology, 2007, 17, 416-21.	0.3	11
124	Skeletal muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell cancer – A multicenter population-based cohort study. Clinical Nutrition, 2022, 41, 131-143.	2.3	11
125	Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands. Cancer Treatment and Research Communications, 2022, 31, 100553.	0.7	11
126	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	1.1	9

#	Article	IF	CITATIONS
127	Predictors of surgical treatment burden, outcomes, and overall survival in older adults with basal cell carcinoma: Results from the prospective, multicenter BATOA cohort. Journal of the American Academy of Dermatology, 2022, 86, 1010-1019.	0.6	9
128	A Germline Homozygote Deletion of the Glutathione-S-Transferase Mu1 Gene Predisposes to Bladder Cancer. Urologia Internationalis, 2000, 64, 134-138.	0.6	8
129	Modest improvement in 20years of kidney cancer care in the Netherlands. European Journal of Cancer, 2012, 48, 1822-1830.	1.3	8
130	New insights into the aetiology of scrotal cancer, a nationwide case ontrol study in the Netherlands. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 65-71.	1.3	8
131	Reproducibility of self-reported melanoma risk factors in melanoma patients. Melanoma Research, 2014, 24, 592-601.	0.6	8
132	Impact of mitotic activity on the pathological substaging of pT1 cutaneous melanoma. British Journal of Dermatology, 2014, 170, 874-877.	1.4	8
133	The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited. Prostate, 2016, 76, 897-904.	1.2	8
134	Imaging and T Category for Prostate Cancer in the 8th Edition of the Union for International Cancer Control TNM Classification. European Urology Oncology, 2020, 3, 563-564.	2.6	7
135	Sex differences in treatment patterns for non-advanced muscle-invasive bladder cancer: a descriptive analysis of 3484 patients of the Netherlands Cancer Registry. World Journal of Urology, 2022, 40, 2275-2281.	1.2	7
136	One arbon metabolism biomarkers and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition. International Journal of Cancer, 2019, 145, 2349-2359.	2.3	6
137	Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study. European Urology Focus, 2021, 7, 332-339.	1.6	6
138	Absence of karyotype abnormalities in patients with familial urothelial cell carcinoma. Urology, 2001, 57, 266-269.	0.5	5
139	Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer. Journal of Patient-Reported Outcomes, 2021, 5, 96.	0.9	5
140	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	0.8	5
141	Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, e346-e352.	0.9	5
142	Hospital volume is associated with postoperative mortality after radical cystectomy for treatment of bladder cancer. BJU International, 2021, 128, 511-518.	1.3	4
143	Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 60.e1-60.e1.	0.8	4
144	Using Explainable Machine Learning to Explore the Impact of Synoptic Reporting on Prostate Cancer. Algorithms, 2022, 15, 49.	1.2	4

#	Article	IF	CITATIONS
145	Self-reported acne is not associated with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 941-945.	0.8	3
146	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
147	Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors. Prostate Cancer and Prostatic Diseases, 2019, 22, 337-343.	2.0	3
148	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. Clinical Genitourinary Cancer, 2022, 20, 43-52.	0.9	3
149	Nonâ€metastatic muscleâ€invasive bladder cancer: the role of age in receiving treatment with curative intent. BJU International, 2022, 130, 764-775.	1.3	3
150	Limited role for histopathological examination of re-excision specimens of completely excised melanomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 225-231.	1.4	2
151	The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands. Bladder Cancer, 2022, , 1-17.	0.2	2
152	Interlaboratory Gleason grading variation affects treatment: a Dutch historic cohort study in 30 509 patients with prostate cancer. Journal of Clinical Pathology, 2023, 76, 690-697.	1.0	2
153	1719 PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH RECURRENCE OF MUSCLE INVASIVE BLADDER CANCER AFTER TREATMENT WITH CURATIVE INTENT. Journal of Urology, 2010, 183, .	0.2	1
154	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Focus, 2021, 7, 788-796.	1.6	1
155	Incidence and survival trends of cancers diagnosed in young adults (20-39 years): A population-based study Journal of Clinical Oncology, 2017, 35, 1567-1567.	0.8	1
156	Determination of serum liver tests during therapy with coumarin anticoagulants. Journal of Hepatology, 1999, 31, 778-779.	1.8	0
157	MP65-10 DELAYED RADICAL CYSTECTOMY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER: A NATIONWIDE ANALYSIS. Journal of Urology, 2015, 193, .	0.2	0
158	PD47-05 ELDERLY PROSTATE CANCER PATIENTS HAVE A WORSE PROGNOSIS THAN YOUNGER PATIENTS: A POPULATION-BASED STUDY IN THE NETHERLANDS Journal of Urology, 2017, 197, .	0.2	0
159	Survival of adolescents and young adults (AYAs) with skeletal Ewing sarcoma: A Dutch population-based study Journal of Clinical Oncology, 2014, 32, 10530-10530.	0.8	0
160	International comparison of treatment and outcome in older patients with muscle-invasive bladder cancer Journal of Clinical Oncology, 2015, 33, e20517-e20517.	0.8	0